Clinical Study “Relaxin for Heart Failure with preserved Ejection Fraction (HFpEF)”

2022-12-16T17:54:11+01:0011.2020|

Relaxera is designing a clinical phase II study demonstrating the beneficial and pleiotropic effects of relaxin in heart failure with preserved ejection fraction (HFpEF). Relaxera plan to commence this study within the next 3 years. The selection of patients for this upcoming study is the responsibility of the Prinicipal Investigators (the physicians in charge of [...]